Lupin acquires Gavis and Novel Labs in US

Lupin Limited has signed an agreement to acquire privately held Gavis Pharmaceuticals LLC and Novel Laboratories Inc (Gavis) for a value of USD 880 million. The sale is subject to certain closing conditions. Gavis is a privately held company specialising in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products. The acquisition enhances scale of Lupins operations in the US generic market and also broadens its range in dermatology, controlled substance products and other high-value and niche generics.

Company Profile : Lupin Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.